Display options
Cite
Jamali R, Mofid A, Vahedi H, et al. The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Hepat Mon. 2013;13(12):e14679doi: 10.5812/hepatmon.14679.
Jamali, R., Mofid, A., Vahedi, H., Farzaneh, R., & Dowlatshahi, S. (2013). The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Hepatitis monthly, 13(12), e14679. https://doi.org/10.5812/hepatmon.14679
Jamali, Raika, et al. "The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial." Hepatitis monthly vol. 13,12 (2013): e14679. doi: https://doi.org/10.5812/hepatmon.14679
Jamali R, Mofid A, Vahedi H, Farzaneh R, Dowlatshahi S. The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Hepat Mon. 2013 Dec 06;13(12):e14679. doi: 10.5812/hepatmon.14679. eCollection 2013. PMID: 24358044; PMCID: PMC3867002.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2013 Dec 06;13(12):e14679. doi: 10.5812/hepatmon.14679. eCollection 2013.

The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial.

Hepatitis monthly

Raika Jamali, Alireza Mofid, Homayoon Vahedi, Rojin Farzaneh, Shahab Dowlatshahi

Affiliations

  1. Student Scientific Research Center, Tehran University of Medical Sciences, Tehran, IR Iran.
  2. Internal Medicine Ward, Sina Hospital, Tehran University of Medical Sciences, Tehran, IR Iran.
  3. Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran.

PMID: 24358044 PMCID: PMC3867002 DOI: 10.5812/hepatmon.14679

Abstract

BACKGROUND: The role of Helicobacter pylori (HP) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) is unclear.

OBJECTIVES: The aim of this study was to evaluate the effect of HP eradication on liver fat content (LFC), liver function tests (LFT), lipid profile, and homeostasis model assessment-IR (HOMA-IR) index in NAFLD.

PATIENTS AND METHODS: Dyspeptic patients with increased serum aminotransferase levels were enrolled in the study. The exclusion criteria were factors affecting serum aminotransferase or HP treatment strategy. Participants with persistent elevated serum aminotransferase level and ultrasound criteria for identification of fatty liver were presumed to have NAFLD. "NAFLD liver fat score" was used to classify NAFLD. Those with "NAFLD liver fat score" greater than -0.64 and positive results for urea breath test (UBT), were included. Lifestyle modification was provided to all participants. HP eradication was performed in intervention arm. LFC, fasting serum glucose (FSG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), triglyceride (TG), cholesterol (CHOL), high and low-density lipoprotein (HDL, LDL), and HOMA-IR were checked at baseline and after that, at intervals of eight weeks and twenty four weeks.

RESULTS: One hundred (49 males) patients with the mean age of 43.46 (± 11.52) were studied. Repeated measure ANOVA showed a significant reduction in LFC, anthropometric measurements, and laboratory parameters (except for HDL) in the both groups during the study; however, no significant difference was observed between the groups.

CONCLUSIONS: It seems that HP eradication per se might not affect LFC, LFT, lipid profile, and insulin resistance in dyspeptic NAFLD patients.

Keywords: Alanine Transaminase; Aspartate Aminotransferases; Helicobacter Pylori; Insulin Resistance; Non-alcoholic Fatty Liver Disease

References

  1. J Clin Pathol. 2004 Dec;57(12):1273-7 - PubMed
  2. Dig Dis Sci. 2009 Jul;54(7):1456-9 - PubMed
  3. Gut. 2003 May;52(5):637-40 - PubMed
  4. Hepatology. 2010 Jan;51(1):121-9 - PubMed
  5. Metabolism. 2010 Feb;59(2):177-85 - PubMed
  6. Am J Gastroenterol. 2008 Dec;103(12):3005-10 - PubMed
  7. Cancer Detect Prev. 2003;27(6):494-7 - PubMed
  8. Diabetes Care. 2004 Jun;27(6):1487-95 - PubMed
  9. J Dig Dis. 2011 Feb;12(1):38-44 - PubMed
  10. Eur J Gastroenterol Hepatol. 2008 Jan;20(1):33-6 - PubMed
  11. Medicina (Kaunas). 2007;43(1):32-5 - PubMed
  12. Arch Iran Med. 2008 Nov;11(6):602-7 - PubMed
  13. Hepatobiliary Pancreat Dis Int. 2012 Oct;11(5):513-20 - PubMed
  14. Helicobacter. 2009 Oct;14(5):144-50 - PubMed
  15. J Med Microbiol. 1995 Jan;42(1):48-52 - PubMed
  16. Gastroenterology. 2009 Sep;137(3):865-72 - PubMed
  17. World J Gastroenterol. 2008 May 14;14(18):2867-71 - PubMed
  18. Arch Intern Med. 2005 Jul 11;165(13):1552-5 - PubMed
  19. Digestion. 2001;63 Suppl 1:93-6 - PubMed
  20. Eur Rev Med Pharmacol Sci. 2011 Sep;15(9):1090-5 - PubMed
  21. J Hepatol. 2003 May;38(5):681-7 - PubMed
  22. Scand J Gastroenterol. 2005 Sep;40(9):1032-41 - PubMed
  23. Lancet Infect Dis. 2008 Apr;8(4):254-60 - PubMed
  24. Med Hypotheses. 2000 Feb;54(2):275-7 - PubMed
  25. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12511-6 - PubMed
  26. Aliment Pharmacol Ther. 2001 Mar;15(3):411-6 - PubMed
  27. Eur J Gastroenterol Hepatol. 2013 Jan;25(1):107-10 - PubMed
  28. Metabolism. 2013 Jan;62(1):121-6 - PubMed
  29. ARYA Atheroscler. 2011 Spring;7(1):31-9 - PubMed
  30. Gan To Kagaku Ryoho. 2011 Mar;38(3):362-4 - PubMed

Publication Types